HALOGENALLILAMINE DERIVATIVES AND THEIR APPLICATIONS Russian patent published in 2023 - IPC C07D471/04 A61K31/472 A61P3/00 

FIELD: pharmaceuticals.

SUBSTANCE: invention relates to a compound of formula I or a pharmaceutically acceptable salt thereof, wherein R₁ and R₂ are each independently selected from hydrogen and halogen and both R₁ and R₂ are not hydrogen; R₃ and R₄ are each independently hydrogen; R₅ and R₆ are each independently hydrogen; L₁ is missing; Cy₁ is a group which is unsubstituted or substituted by one or more R^a shown in the general formula (A-1), (A-2), (A-3), (a), (b) or (c) below:

m is an integer which is either 1 or 2 and n is 0; Y₁, Y₂, Y₃ and Y₄ are each independently selected from CH₂, CH, NH and C=O; X₁, X₂, X₃, X₄, X₉ and X₁₀ are each independently selected from CH, N, O and C=O; X₅, X₆, X₇ and X₈ are each independently selected from CH and N and at least one of X₁, X₂ and X₃ is N; each R^a is independently selected from cyano, halogen, C_1-6 alkyl, C_1-6 alkoxy C_1-6 alkyl, C_1-6 alkylaminocarbonyl, aminocarbonyl, di(C_1-6 alkyl)aminocarbonyl, Cy₂-, Cy₂-C_1-6 alkyl, Cy₂-carbonyl and Cy₂-aminocarbonyl, unsubstituted or substituted with one to three R^b, Cy₂ is a 3–6 membered cycloalkyl, 4–6 membered heterocyclyl, which refers to non-aromatic a cyclic group formed by substitution of cyclic carbon atoms from 1 to 2 heteroatoms selected from O and N, or phenyl; each R^b is independently selected from halogen, C_1-6 alkyl and C_1-6 alkoxy; with the proviso that when Cy₁ corresponds to a group of formula (c), the group of formula (c) is substituted with one or more R^a; with the proviso that when Cy₁ corresponds to formula (b), X₁, X₂, X₃, X₉ and X₁₀ do not represent C=O; denotes a single bond or a double bond; and denotes a double bond, optionally present in the ring structure. The invention also relates to a pharmaceutical composition based on the said compound.

EFFECT: new compounds and a pharmaceutical composition based on them have been obtained, which can be used in medicine in the manufacture of a drug for the prevention and/or treatment of a disease associated with the SSAO/VAP-1 protein.

11 cl, 5 tbl, 48 ex